Treatment of Knee Osteoarthritis (KOA) by Injection of Autologous Adipose-derived Vascular Matrix Components (SVF) Into Joint Cavity

Clinical Study on the Safety and Efficacy of Intrarticular Injection of Autologous Adipose-derived Vascular Matrix Components (SVF) in the Treatment of Knee Osteoarthritis (KOA)

The purpose of this study was to analyze and study the efficacy and safety of autologous adipose-derived vascular matrix components (SVF) in patients with knee osteoarthritis before and after treatment through clinical evaluation, radiation index, and metabolic index comparison between plasma and irrigation solution before and after SVF injection.

Inclusion Criteria:

• The age range is 20-70 years old
• Patients with unilateral or bilateral knee degenerative inflammation (KOA) with Kellgren-lawrence rating of level 3 or lower
• The physical health status is mainly in the ASA grade Ⅰ, Ⅱ and Ⅲ
• Subjects had no active tumors, no active inflammation, no treponema pallidum, HIV, hepatitis B virus, or hepatitis C virus
• The subject shall provide the physical examination report of knee X-ray examination, MRI examination and other items

Exclusion Criteria:

• Patients with nonunion or displaced fractures around defective cartilage
• Pregnant or lactating women
• Autoimmune disease
• Subjects with diabetes (exceptions are patients whose blood sugar levels remain within the normal range and diabetes has not caused other complications)
• The patients had severe neurological diseases affecting the evaluation of postoperative results